This is a group of inherited diseases affecting the nerves. It happens when a protein called amyloid builds up in the nerves. This buildup causes nerve damage and symptoms like muscle weakness, pain, and problems with balance. It's called 'familial' because it runs in families.
Every report comes from a Lived member, sent anonymously.
Have you tried Amvuttra (Vutrisiran) for Familial Amyloid Neuropathies?
Familial amyloid neuropathies are inherited diseases in which an abnormal protein builds up as clumps called amyloid in and around the nerves, gradually damaging them. The nerves most affected are the peripheral nerves, which carry feeling and movement signals to the limbs, and the autonomic nerves, which run automatic functions such as blood pressure, digestion, bladder control, sweating and sexual function. The most common form by far is hereditary transthyretin amyloidosis, often shortened to hATTR or ATTRv and once called familial amyloid polyneuropathy. Transthyretin is a protein made mainly in the liver. The disease typically starts with burning pain, tingling, numbness or loss of temperature sense in the feet, then climbs to the legs and hands and brings weakness and unsteady walking. Diarrhea or constipation, unintended weight loss, dizziness on standing, erectile problems and carpal tunnel syndrome are common. The same deposits often affect the heart and can also affect the eyes and kidneys, so this is a whole-body disease rather than only a nerve disorder. Rarer forms come from other proteins. In gelsolin amyloidosis (the Finnish type), clouding of the cornea usually appears first, followed in middle age by weakness of the face, numbness and loose, sagging skin.
These conditions are caused by a variant in a single gene, most often the TTR gene, which holds the instructions for transthyretin. The altered protein is unstable: transthyretin normally travels in the blood as a group of four linked units, and the variant makes that group fall apart so the pieces misfold and stick together as amyloid. More than 140 TTR variants are known, and which one a family carries influences when symptoms start and whether the nerves or the heart are mainly affected. The inheritance is autosomal dominant, meaning one altered copy from either parent is enough, and each child of a carrier has a 50 percent chance of inheriting it. Inheriting the variant is not the same as getting sick. Some carriers develop symptoms in their twenties or thirties, others not until their seventies, and some never do, even within the same family. The disease is especially common in parts of Portugal and Sweden, but it occurs worldwide. Nothing a person does triggers it.
Diagnosis often takes time because the early symptoms resemble far more common causes of neuropathy, such as diabetes or heavy alcohol use, and the condition is sometimes mistaken for an inflammatory nerve disease called chronic inflammatory demyelinating polyneuropathy (CIDP). Clues that point toward it are a neuropathy that worsens steadily over months, problems with automatic body functions at the same time, heart or eye involvement, carpal tunnel syndrome, or a relative with a similar illness. A genetic test on a blood sample confirms the transthyretin form by finding a disease-causing TTR variant. A small tissue sample (biopsy) from abdominal fat, salivary gland, skin or nerve can show the amyloid itself, though a negative biopsy does not rule the disease out because deposits are patchy. Nerve conduction studies measure how well the larger nerves carry signals, and autonomic tests look at blood pressure on standing and sweating. Because the disease reaches beyond the nerves, the evaluation usually includes heart tests (sometimes a specialized nuclear heart scan that can detect transthyretin amyloid), an eye exam and kidney tests. Relatives can choose predictive genetic testing, ideally with a genetic counselor, since a positive result has implications for planning, monitoring and family members.
For the transthyretin form, treatment now targets the cause. Gene-silencing medicines instruct the liver to make much less transthyretin, which slows or halts the buildup of new amyloid. The three main ones approved in the US for adults with the nerve disease are vutrisiran (Amvuttra), an injection under the skin given by a clinician every 3 months; eplontersen (Wainua), a monthly injection a person can give themselves with an autoinjector; and patisiran (Onpattro), an IV infusion every 3 weeks that requires premedication to prevent infusion reactions. US specialist guidance recommends a gene silencer as first-line treatment, started as soon as possible after diagnosis. These medicines slow progression and can stabilize or modestly improve symptoms and quality of life for some people, but nerve function that is already lost is usually not regained, which is why early treatment matters so much. They lower vitamin A in the blood, and low vitamin A can cause poor vision in dim light or dry eyes. People taking them are advised to take a supplement at the standard daily recommended amount, and not more: the blood level stays low on treatment and does not show how much vitamin A the body actually has, so extra doses are not used to raise it. Stabilizer medicines take a different approach by holding the transthyretin protein together so it cannot break apart. Tafamidis (Vyndaqel) is approved in the US for the heart form of the disease and in Europe for early nerve disease. Diflunisal, an older anti-inflammatory pain reliever, is sometimes used, but its effects on the kidneys, heart and bleeding limit who can take it. Liver transplant, the first treatment aimed at the cause, replaces the main source of the altered protein, but it means major surgery and lifelong immune-suppressing medicine and is not recommended for older people or those with advanced disease or heart involvement. Supportive care is just as important: medicines for nerve pain, treatment for diarrhea and blood pressure drops on standing, physical therapy, braces to support weak ankles, and careful foot care. Gelsolin amyloidosis and other rare forms do not respond to these transthyretin medicines, and their care centers on the eyes, nerves and skin.
Without treatment, the transthyretin nerve disease usually progresses steadily, from symptoms in the feet, to needing a cane or walker, to depending on a wheelchair, and on average it has been fatal within about 7 to 11 years of onset, mostly through heart failure, wasting and infection. Approved treatments have changed this outlook, slowing the disease and improving survival and quality of life for many people, although how much depends on how early treatment starts and on the specific variant. Living with the condition usually means care from a specialized amyloidosis center with a team that may include a neurologist, cardiologist, eye doctor and genetic counselor. Visits every 6 months or so track nerve function, weight, heart and eyes, and the treatment may be changed if the disease keeps progressing. Numb feet cannot feel injuries, so daily foot checks help prevent painless sores from becoming serious infections. Dizziness on standing, bowel problems and fatigue can affect work and daily routines, and physical therapy helps maintain strength and walking. For carriers without symptoms, there is no approved treatment yet, but regular check-ups, often yearly and starting about 10 years before the age symptoms began in affected relatives, aim to catch the earliest signs so treatment can start promptly. Research into gene editing and medicines that clear existing amyloid is ongoing.
Arrange an evaluation if numbness, burning pain or weakness in the feet keeps progressing without a clear cause, especially alongside digestive problems, dizziness on standing or a family history of amyloidosis. Relatives of someone with a confirmed variant should talk with a genetic counselor or specialist about testing and monitoring. If you are already diagnosed, contact your care team promptly about new or faster-worsening symptoms, dizziness or near-fainting on standing, episodes of a racing or fluttering heartbeat, gradually increasing breathlessness or ankle swelling, a foot wound or sore that is not healing, ongoing diarrhea with weight loss, or trouble seeing in dim light while taking a gene-silencing medicine (a possible sign of low vitamin A). Because the disease often affects the heart's electrical system, call 911 for fainting that comes on suddenly without warning or during physical activity, or for a very slow or irregular heartbeat with lightheadedness, chest pain or severe breathlessness at rest. These can signal a dangerous heart rhythm problem that needs same-day treatment, sometimes a pacemaker.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Familial Amyloid Neuropathies is like, what's helped you, or ask the community a question.